ACT 774312
Alternative Names: ACT-774312Latest Information Update: 28 Jun 2021
Price :
$50 *
At a glance
- Originator Actelion Pharmaceuticals
- Developer Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- Class Antiallergics; Antiasthmatics
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Nasal polyps
- No development reported Asthma
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Asthma in Unknown (PO)
- 24 Nov 2020 Idorsia Pharmaceuticals completes a phase II trial in Nasal polyps in Germany and Belgium (NCT03688555)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Nasal polyps in Switzerland (PO, Capsule)